Benign Prostatic Hyperplasia
At a glance
- Assess: record symptom pattern, IPSS/bother, medications, urinalysis, prostate findings and emptying; use a diary for frequency/nocturia. Low flow or high PVR alone does not prove prostatic obstruction. Assess prostate size/anatomy when it will change treatment.[12]
- Options: observation and behavioural measures, medication matched to symptoms/progression risk, or a procedure matched to anatomy, comorbidity and sexual priorities. Use the BPH treatment atlas and the 2026 AUA guideline for procedure-specific selection.[11][12]
- Reconsider the pathway: retention, recurrent infection, stones, hematuria or renal deterioration need directed assessment; exclude stricture, bladder dysfunction and other causes of LUTS. Select pressure-flow testing when diagnostic uncertainty can change management.[12][13]
- Follow-up: reassess symptoms, bother, adverse effects and sexual function after treatment; repeat flow/PVR or renal evaluation as indicated. Long-term medication review should include progression risk and whether the original goals are being met.[12]
Compare progression prevention and preoperative urodynamics evidence. Agent doses remain in the linked pharmacology hubs.
Benign prostatic hyperplasia (BPH) is histologic proliferation of epithelial and stromal cells in the prostate transition zone. It becomes clinically relevant when benign prostatic enlargement produces lower urinary tract symptoms (LUTS), benign prostatic obstruction (BPO), urinary retention, infection, bladder stones, hematuria, renal deterioration, or quality-of-life impairment.[1][2][3]
For the reconstructive urologist, BPH is not just "large prostate disease." It is the most common reversible cause of male outlet obstruction, the background condition that complicates neurogenic and OAB phenotypes, and the upstream driver of many iatrogenic problems: bladder neck contracture, urethral stricture after instrumentation, post-TURP incontinence, recurrent retention, and difficult catheterization.
For procedural selection across endoscopic, minimally invasive, and surgical options, see the BPH & Male LUTS treatment atlas.
Terminology
| Term | Meaning | Practical use |
|---|---|---|
| BPH | Histologic hyperplasia of prostatic epithelial and stromal cells | Tissue diagnosis; often used clinically as shorthand |
| BPE | Benign prostatic enlargement | Size / volume descriptor |
| BPO | Benign prostatic obstruction | Outlet obstruction caused by BPE |
| BOO | Bladder outlet obstruction | Functional obstruction at bladder outlet from any cause: BPH, urethral stricture, bladder neck contracture, dysfunctional voiding |
| LUTS | Lower urinary tract symptoms | Symptom syndrome; may be storage, voiding, or post-micturition |
The distinction matters because not all male LUTS are BPH, and not all enlarged prostates are obstructive.
Epidemiology
BPH increases with age and is nearly universal histologically in older men, but symptomatic disease is the clinically important phenotype.[2][3]
- Histologic BPH begins after age 40 and rises steadily with age.
- Moderate to severe LUTS affect roughly one-third of men aged 50-80 in population surveys.
- More than half of men in their 60s and most octogenarians report some LUTS.
- BPH/LUTS produces a large outpatient, emergency, and procedural burden, including acute urinary retention, medication use, and outlet surgery.
The key clinical point is heterogeneity: two men with the same prostate volume can have very different symptoms, flow rates, PVRs, bladder compliance, and treatment response.
Pathophysiology
BPH has static, dynamic, and bladder-response components.
Static obstruction
Transition-zone enlargement compresses or distorts the prostatic urethra. Median lobe / intravesical protrusion can create a ball-valve outlet obstruction even when total prostate volume is not enormous.
Dynamic obstruction
Alpha-1 adrenergic tone in prostatic stroma and bladder neck smooth muscle increases outlet resistance. This is why alpha blockers can improve symptoms within days without shrinking the prostate.[1][4]
Androgen dependence
Dihydrotestosterone (DHT), produced from testosterone by 5-alpha reductase, is central to prostate growth. 5-alpha reductase inhibitors reduce DHT, shrink the gland over months, lower PSA by roughly half, and reduce progression risk in men with enlarged prostates.[1][5]
Bladder remodeling
Chronic obstruction causes detrusor hypertrophy, trabeculation, diverticula, impaired compliance, detrusor overactivity, and eventually detrusor underactivity. This is the reason outlet surgery can fix the obstruction but not always the storage symptoms or weak bladder.
Risk Factors
| Category | Risk factors |
|---|---|
| Non-modifiable | Age, family history, androgen exposure |
| Metabolic | Obesity, metabolic syndrome, diabetes, hypertension |
| Inflammatory | Prostatic inflammation, recurrent infection, elevated inflammatory markers |
| Lifestyle | Sedentary behavior, smoking, diet-associated cardiometabolic disease |
| Anatomic / disease | Large prostate volume, intravesical median lobe, high PSA as a surrogate for epithelial volume |
Clinical Presentation
Voiding symptoms
- Hesitancy
- Weak stream
- Intermittency
- Straining
- Prolonged voiding
- Terminal dribbling
- Incomplete emptying
- Acute or chronic retention
Storage symptoms
- Frequency
- Urgency
- Nocturia
- Urgency urinary incontinence
- Dysuria or bladder discomfort
Storage symptoms may be caused by obstruction-driven detrusor overactivity, coexisting OAB, nocturnal polyuria, sleep disease, diabetes, diuretics, or neurogenic lower urinary tract dysfunction.
Post-micturition symptoms
- Post-void dribbling
- Sensation of incomplete emptying
Evaluation
Evaluation should answer four questions:
- Are symptoms bothersome enough to treat?
- Is BPH likely to be the driver?
- Is there a complication that requires active intervention?
- Is the prostate anatomy appropriate for medication, MIST, endoscopic surgery, or simple prostatectomy?
Core evaluation
| Step | Why it matters |
|---|---|
| History | LUTS subtype, bother, retention episodes, infections, hematuria, stones, neurologic disease, constipation, sleep symptoms, fluid/caffeine/alcohol pattern |
| Medication review | Diuretics, antihistamines, anticholinergics, sympathomimetics, opioids, antidepressants, decongestants |
| IPSS / QoL score | Best routine tool to quantify severity and follow response[1] |
| Focused exam + DRE | Nodules, tenderness, anal tone, neurologic clues; DRE estimates size poorly |
| Urinalysis | Screens for infection, hematuria, glycosuria, proteinuria |
| PVR | Detects incomplete emptying and retention risk |
| Uroflowmetry | Low Qmax supports obstruction or detrusor weakness; shape of curve matters |
IPSS interpretation
| IPSS | Severity | Usual implication |
|---|---|---|
| 0-7 | Mild | Watchful waiting if not bothered |
| 8-19 | Moderate | Behavioral therapy, medication, or procedure depending on bother |
| 20-35 | Severe | Active therapy; assess for complications and anatomy |
A decrease of 3 points or more is usually considered clinically meaningful.
PSA and prostate size
PSA is not required for every LUTS evaluation. Use shared decision-making for prostate cancer screening, and obtain PSA when the result would change management, life expectancy makes cancer detection relevant, or PSA will help estimate prostate volume and progression risk.[1][4]
If starting a 5-alpha reductase inhibitor or planning intervention, prostate volume should be measured more accurately than DRE, usually by ultrasound, cystoscopy estimate, MRI, CT, or transrectal ultrasound depending on context.[1]
Additional testing before intervention
| Test | Use |
|---|---|
| Cystoscopy | Median lobe, bladder neck, urethral stricture, bladder stones, tumors, prior surgery anatomy |
| Prostate imaging | Volume, shape, median lobe, surgical planning |
| Pressure-flow urodynamics | Distinguishes obstruction from detrusor underactivity when the diagnosis is uncertain |
| Renal ultrasound / creatinine | High PVR, retention, hydronephrosis concern, recurrent infection, renal insufficiency |
| Voiding diary | Nocturia, polyuria, frequency-volume mismatch |
Red Flags and Alternative Diagnoses
Do not anchor on BPH when the pattern suggests another outlet or bladder disorder.
| Finding | Consider |
|---|---|
| Hematuria | Malignancy, stone, infection, BPH bleeding |
| Recurrent UTI | Retention, stone, chronic prostatitis, stricture |
| Very low flow with small prostate | Urethral stricture, bladder neck contracture, detrusor underactivity |
| Severe urgency with normal flow/PVR | OAB, nocturnal polyuria, neurologic disease |
| New neurologic symptoms | Spinal disease, Parkinson disease, stroke, diabetic neuropathy |
| Prior TURP / HoLEP / prostatectomy | Bladder neck contracture, VUAS, urethral stricture |
Natural History
BPH/LUTS may remain stable, improve with self-management, or progress.[4][5]
Clinical progression includes:
- IPSS increase of 4 points or more
- Acute urinary retention
- Recurrent UTI from incomplete emptying
- Bladder stones
- New overflow or urgency incontinence
- Renal insufficiency or hydronephrosis
- Need for invasive BPH therapy
Risk factors for progression include older age, higher baseline IPSS, low Qmax, high PVR, large prostate volume, and higher PSA.
Treatment Strategy
Treatment is symptom- and bother-driven unless complications force intervention. The practical sequence is:
- Mild or low-bother symptoms — watchful waiting and behavioral therapy.
- Bothersome LUTS without complications — medication selected by phenotype and prostate size.
- Medication failure, retention, complications, or patient preference — procedural therapy selected by prostate anatomy, durability goals, sexual-function priorities, anticoagulation, and anesthetic risk.
Conservative Management
Self-management can meaningfully improve LUTS and should be offered before or alongside medication.[1]
- Limit evening fluids.
- Reduce caffeine and alcohol.
- Avoid large fluid boluses.
- Time diuretics earlier in the day when medically safe.
- Treat constipation.
- Use timed voiding or double voiding.
- Use bladder training for urgency/frequency.
- Consider pelvic floor therapy for urgency suppression and post-void dribbling.
- Address sleep apnea and nocturnal polyuria when nocturia is the dominant complaint.
Pharmacologic Therapy
Alpha blockers
Alpha blockers are first-line medication for bothersome moderate to severe LUTS when rapid symptom relief is desired.[1][4]
| Agent group | Examples | Best use | Main trade-offs |
|---|---|---|---|
| Uroselective | Tamsulosin, silodosin, alfuzosin | Rapid LUTS relief; alfuzosin is clinically uroselective without alpha-1A subtype selectivity | Ejaculatory effects vary; orthostasis and intraoperative floppy iris syndrome remain relevant |
| Non-uroselective | Doxazosin, terazosin | Selected patients after assessing blood pressure and medication interactions | More systemic blood-pressure effects; titration required |
Expected onset is days to weeks. Alpha blockers do not shrink the prostate and do not reliably prevent long-term progression by themselves.
5-alpha reductase inhibitors
For symptom improvement, AUA 2026 recommends a 5-ARI with demonstrable enlargement (volume >30 cc and/or PSA >1.5 ng/mL, interpreted in context). Progression prevention is a separate goal to discuss in men at risk; these medicines do not offer rapid symptom relief.[11]
Clinical points:
- Onset is slow: 3-6 months for noticeable benefit, up to 12 months for full effect.
- PSA falls by about 50%; adjust interpretation for cancer screening.
- Sexual adverse effects include lower libido, erectile dysfunction, ejaculatory change, and gynecomastia.
- Best evidence is in men with larger glands and progression risk.
Daily tadalafil
Daily tadalafil can improve LUTS and erectile function; use the PDE5 inhibitor prescribing hub for regimen and adjustment. It is useful when ED and LUTS coexist, but it is contraindicated with nitrates and must be used carefully with hypotension risk.[1][4]
Combination therapy
| Combination | Use |
|---|---|
| Alpha blocker + 5-ARI | Enlarged prostate plus bothersome symptoms; best medical strategy to reduce progression, retention, and surgery risk[5] |
| Alpha blocker + antimuscarinic | Persistent urgency/frequency with acceptable PVR |
| Alpha blocker + β3 agonist | Storage-predominant symptoms with lower cognitive burden than antimuscarinics |
The AUA 2026 guideline permits daily tadalafil with a uroselective alpha blocker (conditional recommendation, Grade C). Average additional LUTS improvement is small; monitor for additive hypotension. Tadalafil plus a 5-ARI is another option in men with demonstrable enlargement. Select combinations through shared decision-making rather than treating every combination as necessary or ineffective.[11]
Phytotherapy
Saw palmetto is not effective. Some data suggest possible benefit from Pygeum africanum or beta-sitosterol, but product variability and weaker evidence make them adjuncts rather than core therapy.[1]
Procedural Therapy
Indications
Procedural treatment is appropriate for:
- Bothersome LUTS despite medication
- Medication intolerance or preference to avoid chronic medication
- Refractory or recurrent urinary retention attributable to BPO
- Recurrent UTI from incomplete emptying
- Bladder stones
- BPH-related gross hematuria refractory to medical therapy
- Renal deterioration or hydronephrosis from obstruction
- Persistently high PVR with complications or bothersome symptoms after assessment of obstruction and detrusor function; PVR alone does not establish a surgical indication
Procedure selection
Procedure choice depends on prostate volume, median lobe, anticoagulation, anesthesia risk, sexual-function priorities, retention status, and need for durability.
| Procedure | Best fit | Strengths | Trade-offs |
|---|---|---|---|
| TURP | Moderate-size glands without need for enucleation | Durable benchmark, widely available | Retrograde ejaculation common; bleeding, TUR syndrome risk lower with bipolar |
| HoLEP / laser enucleation | Any size, especially large glands or retention | Size-independent, durable, excellent debulking | Learning curve, transient incontinence, retrograde ejaculation common |
| Simple prostatectomy | Very large glands, large median lobe, stones/diverticula needing surgery | Maximal tissue removal | More invasive; bleeding/anesthesia burden |
| GreenLight / laser vaporization | Bleeding-risk patients, moderate glands | Hemostatic outpatient option | Less tissue for pathology; retreatment risk in large glands |
| Aquablation | 30-80 mL glands, ejaculation-preservation priority, selected median lobes | Strong symptom improvement with lower ejaculatory dysfunction than TURP | Bleeding management, availability, retreatment data still maturing[6] |
| Prostatic urethral lift | Lateral-lobe obstruction, smaller/moderate glands, ejaculation preservation | Fast recovery, preserves ejaculation | Less objective flow improvement, retreatment higher than TURP/HoLEP[7] |
| Water vapor therapy | 30-80 mL glands, office-based treatment, sexual preservation | Treats some median lobes, low sexual adverse events | Delayed symptom improvement, catheter period, retreatment risk |
| iTIND | Selected smaller/moderate glands | Temporary implant, ejaculation-preserving intent | Shorter evidence horizon |
| Prostatic artery embolization | High surgical/anesthesia risk, large vascular glands, preference to avoid transurethral surgery | Low sexual adverse-event signal, outpatient IR approach | Less predictable deobstruction; retreatment and anatomy-dependent technical success[8] |
Network meta-analyses consistently show the trade-off: TURP/HoLEP/simple prostatectomy provide stronger objective deobstruction and durability, while MISTs generally preserve sexual function better and carry lower perioperative morbidity at the cost of more retreatment.[9][10]
Retention Pathway
Acute urinary retention from presumed BPH:
- Place urethral catheter gently; use coude catheter early if resistance is expected.
- If urethral catheterization fails, avoid repeated traumatic attempts and place suprapubic drainage.
- Start an alpha blocker unless contraindicated.
- Trial without catheter after several days of decompression and alpha-blocker exposure.
- If trial fails or retention recurs, maintain safe drainage and evaluate anatomy, reversible factors and bladder function; discuss definitive outlet treatment for persistent BPO rather than assuming every failed trial requires immediate surgery.[11][12]
Chronic retention is different. Check renal function, hydronephrosis risk, PVR trend, bladder compliance when relevant, and detrusor contractility before promising that outlet surgery will restore spontaneous voiding.
Complications of BPH
- Acute urinary retention
- Chronic urinary retention
- Recurrent UTI
- Bladder stones
- Gross hematuria
- Hydronephrosis or renal insufficiency
- Bladder diverticula and trabeculation
- Overflow incontinence
- Detrusor overactivity or impaired compliance
- Detrusor underactivity after long-standing obstruction
Reconstructive Pearls
- BPH is a diagnosis of probability, not a reflex label. In men with prior instrumentation, pelvic radiation, urethroplasty, TURP, HoLEP, prostatectomy, or traumatic catheterization, rule out stricture or bladder neck stenosis.
- Low flow does not prove obstruction. A weak detrusor and an obstructed prostate can look identical on uroflow; pressure-flow studies settle the question.
- Storage symptoms may persist after perfect outlet surgery. Counsel men with severe urgency, diabetes, neurologic disease, or long-standing obstruction.
- Median lobe changes the menu. PUL is less suitable in many obstructive median-lobe anatomies; water vapor therapy, TURP, HoLEP, aquablation, or simple prostatectomy may be better.
- Preserving ejaculation usually costs durability or deobstruction. That trade-off is acceptable only if the patient explicitly values it.
- Treat the outlet before continence surgery. In men with SUI plus BPH/BOO, stabilize emptying before sling or AUS planning.
Selected evidence
MTOPS · 2003[5]; UPSTREAM · 2020[13]. The comparison below preserves the study-specific population, denominator, endpoint and uncertainty.
Selected studies, not a systematic review. Outcomes and populations differ; percentages across studies should not be ranked as if they were directly comparable. These source checks do not record a clinician review of the full article.
| Study and population | Comparison and results | Use and limitations |
|---|---|---|
| MTOPS · 2003 Men ≥50 years with symptomatic BPH and reduced urinary flow. Randomized n=3047 | Doxazosin, finasteride or combination vs placebo Clinical progression: symptom worsening, retention, incontinence, renal insufficiency or recurrent UTI · Mean 4.5 years Events per 100 person-years: placebo 4.5; doxazosin 2.7; finasteride 2.9; combination 1.5. Combination reduced relative risk by 66%. P<.001 for combination vs placebo; confidence interval not extracted from inspected results. | Supports combination therapy for appropriately selected men at risk of progression.
|
| UPSTREAM · 2020 Men with bothersome LUTS in whom prostate surgery was an option. Randomized n=820 | Routine care plus urodynamics vs routine care alone International Prostate Symptom Score · 18 months 12.6 with urodynamics vs 13.1 with routine care. Adjusted difference −0.33; 95% CI −1.47 to 0.80; noninferiority margin 1 point. Underwent surgery · 18 months 153/408 (38%) vs 138/384 (36%). Adjusted odds ratio 1.05; 95% CI 0.77–1.43; no reduction in surgery. | Reserve invasive urodynamics for diagnostic uncertainty or situations in which the result can change counselling or treatment.
|
See Also
- BPH & Male LUTS Treatment Atlas
- Alpha Blockers
- 5-alpha Reductase Inhibitors
- Urgency Incontinence and Overactive Bladder
- Underactive Bladder
- Bladder Neck Contracture
- Urethral Stricture
- UroLift
- Energy Devices
References
1. Arnold MJ, Gaillardetz A, Ohiokpehai J. "Benign Prostatic Hyperplasia: Rapid Evidence Review." Am Fam Physician. 2023;107(6):613-622. AAFP
2. Chughtai B, Forde JC, Thomas DD, et al. "Benign Prostatic Hyperplasia." Nat Rev Dis Primers. 2016;2:16031. doi:10.1038/nrdp.2016.31
3. Sarma AV, Wei JT. "Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms." N Engl J Med. 2012;367(3):248-257. doi:10.1056/NEJMcp1106637
4. Wei JT, Dauw CA, Brodsky CN. "Lower Urinary Tract Symptoms in Men: A Review." JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045
5. McConnell JD, Roehrborn CG, Bautista OM, et al. "The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia." N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656
6. Hwang EC, Jung JH, Borofsky M, Kim MH, Dahm P. "Aquablation of the Prostate for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia." Cochrane Database Syst Rev. 2019;2:CD013143. doi:10.1002/14651858.CD013143.pub2
7. Jung JH, Reddy B, McCutcheon KA, et al. "Prostatic Urethral Lift for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia." Cochrane Database Syst Rev. 2019;5:CD012832. doi:10.1002/14651858.CD012832.pub2
8. McWilliams JP, Bilhim TA, Carnevale FC, et al. "Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia." J Vasc Interv Radiol. 2019;30(5):627-637.e1. doi:10.1016/j.jvir.2019.02.013
9. Franco JVA, Jung JH, Imamura M, et al. "Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Cochrane Network Meta-Analysis." BJU Int. 2022;130(2):142-156. doi:10.1111/bju.15653
10. Cornu JN, Zantek P, Burtt G, et al. "Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-Analysis." Eur Urol. 2023;83(6):534-547. doi:10.1016/j.eururo.2023.02.028
11. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026). Parts I–III. doi:10.1097/JU.0000000000005097, Part II, Part III.
12. European Association of Urology. Management of Non-neurogenic Male LUTS, 2026 edition. Diagnostic evaluation; disease management; follow-up. Accessed September 11, 2026.
13. Drake MJ et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. 2020. doi:10.1016/j.eururo.2020.06.004.